TrialAdvances in therapy2024

Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study.

James D Bowen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.